{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:59:18Z","timestamp":1789178358912,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijantimicag.2017.12.011","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T14:15:21Z","timestamp":1514038521000},"page":"608-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016)"],"prefix":"10.1016","volume":"51","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0010","doi-asserted-by":"crossref","first-page":"E855","DOI":"10.3390\/ijms17060855","article-title":"Update on the management of pediatric acute osteomyelitis and septic arthritis","volume":"17","author":"Castellazzi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.surge.2015.12.005","article-title":"The management of osteomyelitis in the adult","volume":"14","author":"Maffulli","year":"2016","journal-title":"Surgeon"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2106\/JBJS.N.01350","article-title":"Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009","volume":"97","author":"Kremers","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0030","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/apa.12115","article-title":"Paediatric bone and joint infections are more common in boys and toddlers: a national epidemiology study","volume":"102","author":"Grammatico-Guillon","year":"2013","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0035","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0040","series-title":"M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0045","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0055","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0060","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijantimicag.2016.04.009","article-title":"In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011\u20132013)","volume":"47","author":"Huband","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0075","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1128\/AAC.01453-08","article-title":"Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates","volume":"53","author":"Biedenbach","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.diagmicrobio.2013.01.002","article-title":"Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes and Micrococcus spp. (1,357 strains)","volume":"76","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0090","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/AAC.00274-15","article-title":"In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program","volume":"59","author":"McCurdy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0095","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jac\/dkv303","article-title":"Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011\u201313)","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0100","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"16","author":"Ramdeen","year":"2015","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0105","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-015-0430-x","article-title":"Dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.12.011_bib0110","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917304454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917304454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T07:33:22Z","timestamp":1542353602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917304454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0924857917304454"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.12.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011\u20132016)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}